246 related articles for article (PubMed ID: 15546111)
1. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
File TM
Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111
[TBL] [Abstract][Full Text] [Related]
2. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
4. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of antibiotic resistance in respiratory tract infections.
Klugman KP
Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
[TBL] [Abstract][Full Text] [Related]
7. Sparfloxacin: a review.
Schentag JJ
Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
[TBL] [Abstract][Full Text] [Related]
8. Short-duration therapy for respiratory tract infections.
Goff DA
Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
Li JZ; Winston LG; Moore DH; Bent S
Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
[TBL] [Abstract][Full Text] [Related]
10. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
Doern GV
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
[TBL] [Abstract][Full Text] [Related]
12. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
13. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
File TM; Schentag JJ
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S157-65. PubMed ID: 18986283
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
15. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
16. Clarithromycin in the management of community-acquired pneumonia.
McCarty JM
Clin Ther; 2000 Mar; 22(3):281-94; discussion 265. PubMed ID: 10963284
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
18. [Antibiotic therapy for community acquired Streptococcus pneumoniae pneumonia: clinical relevance of antibiotic resistance].
Bédos JP; Bruneel F
Med Mal Infect; 2006; 36(11-12):667-79. PubMed ID: 16842956
[TBL] [Abstract][Full Text] [Related]
19. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2005 Dec; 26(6):575-616. PubMed ID: 16388429
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]